Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 3/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1696262 | 1.00 | KDM4E (0.42) | KDM4ECES2CES1MGLLFAAH | |
| SCHEMBL300884 | 0.91 | CA12 (0.42) | KDM4EMGLLMEN1KMT2AMAPT | |
| SCHEMBL18119790 | 0.90 | KDM4E (0.39) | KDM4ECES2CES1MGLLFAAH | |
| SCHEMBL13455758 | 0.85 | SMN1; SMN2 (0.44) | KDM4EMGLLMEN1KMT2ARAB9A | |
| SCHEMBL5648489 | 0.84 | CA12 (0.47) | MEN1KMT2AMAPTRAB9AMAPK1 | |
| SCHEMBL27717830 | 0.84 | CA1 (0.55) | MGLLKMT2AMAPTHTTCA1 | |
| SCHEMBL1800956 | 0.82 | PTPRF (0.44) | KDM4ECES2CES1MAPTNPC1 | |
| SCHEMBL10070313 | 0.82 | ALDH1A1 (0.37) | KDM4EMGLLMEN1KMT2AMAPT | |
| SCHEMBL16005095 | 0.82 | ALDH1A1 (0.37) | KDM4EMGLLMEN1KMT2AMAPT | |
| SCHEMBL12216547 | 0.82 | LMNA (0.44) | KMT2AMAPTNPC1RAB9ACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116761810-A | Imaging and targeting of programmed death ligand-1 (PD-L1) expression | 约翰霍普金斯大学 | 2023-09-15 | — | — | CN | claimed |
| US-20230271923-A1 | IMAGING AND TARGETING PROGRAMMED DEATH LIGAND-1 (PD-LI) EXPRESSION | THE JOHNS HOPKINS UNIVERSTY | 2023-08-31 | — | — | US | claimed |
| CN-112675311-B | 18/19 F-labeled PSMA (PSMA-conjugated diene monomer) targeting diagnosis and treatment integrated small-molecule drug conjugate, and preparation method and application thereof | 西安交通大学医学院第一附属医院 | 2023-06-20 | — | — | CN | claimed |
| EP-4192524-A2 | IMAGING AND TARGETING PROGRAMMED DEATH LIGAND-1 (PD-LI) EXPRESSION | The Johns Hopkins University (US) | 2023-06-14 | — | — | EP | claimed |
| US-11607466-B2 | Tumor and immune cell imaging based on PD-L1 expression | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-03-21 | — | — | US | claimed |
| WO-2022032100-A2 | IMAGING AND TARGETING PROGRAMMED DEATH LIGAND-1 (PD-LI) EXPRESSION | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-02-10 | — | — | WO | claimed |
| CN-112675311-A | 18/19F-labeled PSMA (patterned beam-selective membrane array) targeted diagnosis and treatment integrated small-molecule drug conjugate, and preparation method and application thereof | 西安交通大学医学院第一附属医院 | 2021-04-20 | — | — | CN | claimed |
| EP-3558395-A1 | TUMOR AND IMMUNE CELL IMAGING BASED ON PD-L1 EXPRESSION | The Johns Hopkins University (US) | 2019-10-30 | — | — | EP | claimed |
| CN-110366432-A | Tumour and immunocyte imaging based on PD-L1 expression | 约翰霍普金斯大学 | 2019-10-22 | — | — | CN | claimed |
| US-20190314531-A1 | TUMOR AND IMMUNE CELL IMAGING BASED ON PD-L1 EXPRESSION | THE JOHNS HOPKINS UNIVERSITY | 2019-10-17 | — | — | US | claimed |
| WO-2018119313-A1 | TUMOR AND IMMUNE CELL IMAGING BASED ON PD-L1 EXPRESSION | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-06-28 | — | — | WO | claimed |
| US-12583913-B2 | Antibody specific to Staphylococcus aureus, therapeutic method and detection method using same | CHURCH WILLIAM R (US) | 2026-03-24 | — | — | US | disclosed |
| US-20250375542-A1 | 18F-LABELED PSMA-TARGETED PET IMAGING AGENTS | CANCER TARGETED TECH LLC (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250163104-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2025-05-22 | — | — | US | disclosed |
| US-12139470-B2 | Trioxolane agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-11-12 | — | — | US | disclosed |
| WO-2006032911-A2 | METALLOPROTEINASE INHIBITOR IMAGING AGENTS | GE HEALTHCARE LIMITED (GB) | 2006-03-30 | — | — | WO | disclosed |
| EP-1142890-B1 | AMINOPYRAZOLE DERIVATIVES | TEIKOKU HORMONE MFG CO LTD (JP) | 2005-08-03 | — | — | EP | disclosed |
| US-6511997-B1 | For treatment of a disease associated with tumor necrosis factor alpha, interleukin 1, interleukin 6 or cyclooxygenase II; such as irritable bowel disease | TEIKOKU HORMONE MFG. CO., LTD. (JP) | 2003-01-28 | — | — | US | disclosed |
| CN-1331688-A | Aminopyridine Derivatives | TEIKOKU HORMONE MFG CO LTD (JP) | 2002-01-16 | — | — | CN | disclosed |
| EP-1142890-A1 | AMINOPYRAZOLE DERIVATIVES | TEIKOKU HORMONE MFG. CO., LTD. (JP) | 2001-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12139470-B2 | Trioxolane agents | ABCB4, SLC10A1, SLC10A2 | KDM4E 4796/4885CES2 2373/4885CES1 330/4885 |
| US-20250163104-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | KDM4E 1355/4885CES2 4750/4885CES1 4282/4885 |
| US-12583913-B2 | Antibody specific to Staphylococcus aureus, therapeutic method and detection method using same | IGSF11, VSIG8, VARS1 | KDM4E 1665/4885CES2 3583/4885CES1 1997/4885 |
| US-11607466-B2 | Tumor and immune cell imaging based on PD-L1 expression | CD274, PDCD1LG2, PDCD1 | KDM4E 4444/4885CES2 4488/4885CES1 2996/4885 |
| US-20190314531-A1 | TUMOR AND IMMUNE CELL IMAGING BASED ON PD-L1 EXPRESSION | CD274, PDCD1LG2, PDCD1 | KDM4E 4444/4885CES2 4488/4885CES1 2996/4885 |
| US-20230271923-A1 | IMAGING AND TARGETING PROGRAMMED DEATH LIGAND-1 (PD-LI) EXPRESSION | CD274, PDCD1LG2, PDCD1 | KDM4E 4400/4885CES2 4548/4885CES1 4149/4885 |
| US-20250375542-A1 | 18F-LABELED PSMA-TARGETED PET IMAGING AGENTS | FOLH1, PSMA1, PSMA2 | KDM4E 2380/4885CES2 1560/4885CES1 966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.